^
    BIOMARKER:

    BCR-ABL1 F317L

    i
    Other names: BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
    Entrez ID:
    25; 613
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    BCR-ABL1 F317L
    CML
    dasatinib
    Resistant: A2 - Guideline
    BCR-ABL1 F317L
    CML
    bosutinib
    Resistant: A2 - Guideline
    BCR-ABL1 F317L
    CML
    nilotinib
    Sensitive: A2 - Guideline
    BCR-ABL1 F317L
    ALL
    dasatinib
    Resistant: A2 - Guideline
    BCR-ABL1 F317L
    ALL
    nilotinib
    Sensitive: A2 - Guideline
    BCR-ABL1 F317L
    ALL
    bosutinib
    Resistant: A2 - Guideline
    BCR-ABL1 F317L
    CML
    dasatinib + imatinib
    Resistant: C2 – Inclusion Criteria
    BCR-ABL1 F317L
    CML
    imatinib
    Resistant: C3 – Early Trials